AbbVie Files SNDA For Atogepant For Label Expansion

AbbVie (ABBV) announced it has submitted a supplemental New Drug Application for atogepant to the FDA to support the preventive treatment of chronic migraine in adults. The company noted that the submission is based on pivotal phase 3 PROGRESS chronic migraine study evaluating atogepant in adult patients that met primary endpoint.

Michael Gold, therapeutic area head, neuroscience development, AbbVie, said: "This sNDA approval would also diversify AbbVie's migraine portfolio and make it the only company to offer two approved preventive treatments for those living with chronic migraine."

Atogepant is marketed as QULIPTATM in the U.S. and is approved to treat adults with episodic migraine.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The UK government decided to abandon its plan to scrap the 45 percent tax rate, which was announced just 10 days before, after coming under severe criticism for such a relaxation for the high earners at the time of rising living costs. Russia's manufacturing activity grew at the fastest pace in three-and-a-half years in September, supported by increases in production and new orders, survey data from S&P Global showed on Monday. The factory Purchasing Managers' Index posted 52.0 in September, up from 51.7 in August. A score above... India's manufacturing sector growth slowed moderately in September but the overall growth remained robust, survey data published by S&P Global showed on Monday. The manufacturing Purchasing Managers' Index fell to 55.1 in September from 56.2 in August. The score was also below economists' forecast...
Follow RTT